SCHEMBL15565880

SCHEMBL15565880

O=Cc1ccc(-c2ccc(OCCCF)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
HPGD P15428 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
DRD1 P21728 2/20 0.51
APP P05067 10/20 0.46
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD5 P21918 1/20 0.45
DRD3 P35462 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936686 0.94 ALDH1A1 (0.61) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL8371578 0.87 ALDH1A1 (0.61) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL1982944 0.85 ALDH1A1 (0.58) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL9908262 0.85 ALDH1A1 (0.58) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL3077169 0.84 ALDH1A1 (0.67) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL3925126 0.84 ALDH1A1 (0.57) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL3071964 0.83 ALDH1A1 (0.53) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL8204708 0.82 ALDH1A1 (0.75) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL8551794 0.82 ALDH1A1 (0.69) MAPTALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL5090074 0.82 ALDH1A1 (0.75) MAPTALDH1A1LMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
CN-113754589-B Compositions, methods, and systems for synthesizing and using contrast agents 蓝瑟斯医学影像公司 2024-09-27 CN disclosed
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2024-03-28 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
CN-113754589-A Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-12-07 CN disclosed
CN-107311935-B Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-10-08 CN disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-06-01 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
EP-2882719-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2015-06-17 EP disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 WO disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 MAPT 1255/4885ALDH1A1 3833/4885LMNA 1473/4885
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 MAPT 752/4885ALDH1A1 3040/4885LMNA 1449/4885
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 MAPT 1255/4885ALDH1A1 3833/4885LMNA 1473/4885
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 MAPT 752/4885ALDH1A1 3040/4885LMNA 1449/4885
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 MAPT 752/4885ALDH1A1 3040/4885LMNA 1449/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 MAPT 752/4885ALDH1A1 3040/4885LMNA 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.